Table 1.
Baseline characteristics of participants
| AERD (n=16) | ATA (n=13) | P-value | |
|---|---|---|---|
| Age, y, mean (± SEM) | 37.8 (± 3.2) | 42.6 (± 2.4) | 0.2 |
| Sex (females/males) | 10/6 | 7/6 | 0.5 |
| Race, n (%) | 0.2 | ||
| African-American | 5 (31.2) | 2 (15.4) | |
| Hispanic | 6 (37.5) | 7 (53.8) | |
| White | 5 (31.3) | 3 (23.1) | |
| Other | 1 (7.7) | ||
| Aspirin hypersensitivity duration, years | 4 (± 1.6) | N/A | |
| Presence of nasal polyps (%) | 87.5 | 23.1 | <0.001 |
| ICS/LABA use (%) | 87 | 76 | 0.5 |
| Montelukast use, %* | 37.5 | 50 | 0.6 |
| Baseline FEV1 %predicted, mean (± SEM) | 73.0 (± 3.1) | 92.5 (± 9.4) | 0.3 |
| Nasal peak flow, L/min, mean (± SEM) | 81.7 (± 12.7) | 143 (± 28.1) | 0.04 |
| Absolute eosinophil count/mm3, peripheral blood, mean (± SEM) | 0.6 (± 0.13) | 0.15 (± 0.2) | <0.01 |
| Peripheral blood eosinophils, % leukocytes, mean (± SEM) | 10.0 (± 1.3) | 2.0 (± 1.7) | <0.001 |
| Serum IgE, IU/L, median (IQR) | 198 (102–372) | 288 (172–716) | 0.2 |
| FeNO value (ppb), median (IQR) | 29 (21–104) | 18 (13–23) | 0.01 |
| Urinary LTE4, pg/mg creatinine, median (IQR) | 660.4 (462.6–833.4) | 426.2 (356.2–455.2) | <0.01 |
| Urinary tetranor PGDM, pg/mg creatinine, mean (± SEM) | 6440.3 (± 697.5) | 6698.2 (± 828.2) | 0.8 |
| Plasma PGEM, pg/ml, mean (± SEM) | 38.8 (± 5.6) | 54.9 (± 9.1) | 0.3 |
*
This value represents the percentage of patients in each group taking montelukast throughout the study as part of their medical regimen. All subjects (AERD and ATA) were requested to take 10 mg of montelukast daily during the week prior to the standard graded oral aspirin challenge.